Efficacy, Acceptability and Safety of Event-driven HIV PrEP Using TAF/FTC in MSM in Thailand and France.

Who May Qualify: - Male at birth age ≥ 18 years old - Reporting having sex with men - Negative 4th generation HIV-1 and HIV-2 test - Reporting condomless anal sex with men not more often than two days during the previous month and able to plan their sexual activity - Risk of HIV acquisition based on self-report of at least one of the following behaviors during the 6 months before enrollment: condomless anal sex with at least 2 different sexual partners, sexually transmitted infection (rectal chlamydia and/or rectal gonorrhea and/or syphilis), provided or received money goods or favor in exchange of sex, binge drinking or use of non-injectable recreational drugs. - Consenting to participate and agreeing to follow the clinical trial procedures, including adherence to study visits every 3 months - In France: Person affiliated with or benefiting from a social security system (article L1121-11of the public health code in France) Non-Who May Qualify: - Symptoms and/or clinical signs consistent with an acute HIV infection - Women and trans women - Taking feminizing hormone therapy - Positive HIV test result at screening or enrollment even if HIV infection is not confirmed - Positive hepatitis B surface antigen test - ALT or AST \> 4 ULN - Estimated glomerular filtration rate \< 60mL/min/1.73m² - History of chronic kidney disease, osteoporosis, osteopenia or pathological fracture not related to trauma - Hypersensitivity to the study products F/TDF or F/TAF - Past or concurrent participation in a HIV vaccine trial or concurrent participation in another clinical trial without the agreement of the principal investigators of the two trials - Use of intravenous drugs within the last 12 months - Person under legal guardianship - Not likely to comply with the clinical trial procedures or with any condition incompatible with study participation, upon the investigator's judgement. - Ongoing Post-Exposure Prophylaxis (PEP) for HIV Always talk to your doctor about whether this trial is right for you.